Adam Koppel, Director, 10% Owner at Kailera Therapeutics, Inc. (KLRA), bought 1,562,500 shares at $16.00 ($25.0M) on 2026-04-20, disclosed to the SEC on 2026-04-20.
Director Adam Koppel purchased $25M worth of shares at $16, marking the largest insider trade in the company's history. This significant bet suggests insider confidence in the stock's potential following its recent IPO and analyst coverage.
The stock is currently trading at $24.61, sitting 12.81% below its 52-week high of $28.23 but 3.88% above its 52-week low of $23.69.
Analysts initiated coverage on May 13, 2026, with William Blair highlighting the company's obesity pipeline. Additionally, the stock completed its IPO on May 1, 2026, and the insider purchase represents the largest trade in the company's history.
The stock carries a short interest of 1.51% of the float, which could pressure the price if sentiment turns negative. Additionally, the company trades at a negative forward P/E of -5.6, indicating current expectations of continued losses.
Nothing distinguishes this filing.
| Filing → |
| DRNA | SELL | 2020-12-14 | $23.4M | — | Filing → |
| CERE | BUY | 2020-11-12 | $6.8M | — | Filing → |
| CERE | BUY | 2020-10-29 | $100.0M | — | Filing → |